Nyxoah S.A. (NASDAQ:NYXH) Receives Average Rating of “Moderate Buy” from Brokerages

Nyxoah S.A. (NASDAQ:NYXH) has received an average rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $20.60.

A number of research analysts have commented on the company. Piper Sandler upped their price target on Nyxoah from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target (up previously from $18.00) on shares of Nyxoah in a research report on Wednesday, March 20th. Oppenheimer upped their price target on Nyxoah from $17.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday, March 14th. Stifel Nicolaus upped their price target on Nyxoah from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. Finally, Cantor Fitzgerald upped their price target on Nyxoah from $10.00 to $14.00 and gave the company an “overweight” rating in a research report on Friday, February 9th.

Nyxoah Price Performance

Shares of NASDAQ NYXH opened at $9.30 on Friday. Nyxoah has a fifty-two week low of $4.00 and a fifty-two week high of $20.00. The company has a current ratio of 4.73, a quick ratio of 4.50 and a debt-to-equity ratio of 0.12. The stock has a fifty day moving average of $13.72 and a 200-day moving average of $8.58.

Nyxoah (NASDAQ:NYXH) last posted its earnings results on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). Nyxoah had a negative return on equity of 38.58% and a negative net margin of 993.28%. The business had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $2.01 million. Sell-side analysts forecast that Nyxoah will post -1.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NYXH. Invesco Ltd. purchased a new stake in Nyxoah during the first quarter worth $8,177,000. Sei Investments Co. purchased a new stake in Nyxoah during the second quarter worth $265,000. Millennium Management LLC purchased a new stake in Nyxoah during the fourth quarter worth $51,000. ExodusPoint Capital Management LP purchased a new stake in Nyxoah during the first quarter worth $97,000. Finally, AXA S.A. lifted its holdings in Nyxoah by 1.4% during the first quarter. AXA S.A. now owns 217,000 shares of the company’s stock worth $1,621,000 after buying an additional 3,000 shares during the period.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.